/
Oncology
Cervical Cancer
114
Pipeline Programs↗
208
Active Trials↗
80
Companies Involved↗
Cervical Cancer is a highly competitive landscape with 114 programs across 80 companies. The most active players are Bristol-Myers Squibb, Sichuan Baili Pharmaceutical Co., Ltd., CSPC Megalith Biopharmaceutical Co.,Ltd.. 30 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical28
Phase 14
Phase 252
Phase 330
Approved
No programs
Analysis
Modality Breakdown
66%
Small molecule
67 of 101 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 101 classified programs, each share of the total. Modality classified for 99% of 114 pipeline programs.
Analysis
Trial Status
542
clinical trials
Completed158 · 29%
Recruiting112 · 21%
Unknown status107 · 20%
Not yet recruiting48 · 9%
Terminated45 · 8%
Active, not recruiting44 · 8%
Other28 · 5%
Clinical Trials
Trial Activity
542 trials
A Multicenter, Non-Inferiority, Phase III Randomized Controlled Trial Comparing Moderately Hypofractionated Online Adaptive Radiotherapy（MH-ART） vs. Conventional Fractionated Intensity-Modulated Radiotherapy（CF-IMRT） in Postoperative Cervical Cancer and Endometrial Cancer
Recruiting·—·Preclinical·NCT07584161·228 enrolled
An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer.
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Approved·NCT07776821·31 enrolled
Page 1 of 37
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)